Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) have been given a consensus recommendation of "Hold" by the six research firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $53.00.
Several analysts recently issued reports on the company. Needham & Company LLC raised their target price on Phathom Pharmaceuticals from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, December 15th. Jonestrading began coverage on Phathom Pharmaceuticals in a report on Thursday, January 28th. They set a "buy" rating for the company. Guggenheim initiated coverage on shares of Phathom Pharmaceuticals in a report on Tuesday, February 2nd. They issued a "buy" rating and a $60.00 price target on the stock. BMO Capital Markets began coverage on shares of Phathom Pharmaceuticals in a research report on Wednesday, February 17th. They set an "outperform" rating and a $63.00 price target for the company. Finally, Zacks Investment Research lowered shares of Phathom Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, April 3rd.
In other news, Director David A. Socks sold 22,118 shares of the firm's stock in a transaction on Monday, April 5th. The stock was sold at an average price of $36.05, for a total value of $797,353.90. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Terrie Curran sold 11,513 shares of Phathom Pharmaceuticals stock in a transaction on Monday, March 22nd. The stock was sold at an average price of $43.32, for a total value of $498,743.16. Following the completion of the sale, the insider now directly owns 11,513 shares of the company's stock, valued at approximately $498,743.16. The disclosure for this sale can be found here. In the last quarter, insiders have sold 212,926 shares of company stock worth $9,345,504. Corporate insiders own 39.80% of the company's stock.
Large investors have recently made changes to their positions in the business. Virtus ETF Advisers LLC lifted its holdings in Phathom Pharmaceuticals by 6.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 6,635 shares of the company's stock valued at $220,000 after purchasing an additional 393 shares in the last quarter. Rhumbline Advisers increased its stake in Phathom Pharmaceuticals by 11.7% in the 4th quarter. Rhumbline Advisers now owns 12,200 shares of the company's stock worth $405,000 after buying an additional 1,280 shares in the last quarter. Nuveen Asset Management LLC increased its stake in Phathom Pharmaceuticals by 2.2% in the 4th quarter. Nuveen Asset Management LLC now owns 63,006 shares of the company's stock worth $2,093,000 after buying an additional 1,335 shares in the last quarter. State Street Corp raised its holdings in Phathom Pharmaceuticals by 0.7% during the third quarter. State Street Corp now owns 214,307 shares of the company's stock valued at $7,859,000 after acquiring an additional 1,500 shares during the period. Finally, Citigroup Inc. lifted its position in shares of Phathom Pharmaceuticals by 194.6% in the fourth quarter. Citigroup Inc. now owns 3,294 shares of the company's stock valued at $110,000 after acquiring an additional 2,176 shares in the last quarter. 73.80% of the stock is currently owned by institutional investors and hedge funds.
Shares of PHAT stock opened at $38.73 on Thursday. The business has a 50-day moving average of $43.29 and a 200 day moving average of $40.62. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.21 and a quick ratio of 8.21. Phathom Pharmaceuticals has a 1-year low of $27.47 and a 1-year high of $64.54. The stock has a market capitalization of $1.21 billion, a PE ratio of -2.77 and a beta of 1.32.
Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings data on Monday, March 29th. The company reported ($1.58) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.01) by ($0.57). Analysts anticipate that Phathom Pharmaceuticals will post -3.1 EPS for the current year.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Further Reading: Example of operating income, EBIT and EBITDA
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What is a stock buyback?7 Healthcare Stocks Delivering Innovation in 2021
We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.
Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.
However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.
That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.
View the "7 Healthcare Stocks Delivering Innovation in 2021"